At a glance
ClinicalIndex Comparison RecordN/ACompleted· 18 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Dapagliflozin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Regulation of Hepatic and Peripheral Glucose Metabolism: Protocol IVA. Effect of Plasma Glucose Reduction by Selective SLGT2 Inhibition on Mitochondrial Dysfunction and Impaired Insulin Signaling/Sensitivity in T2DM
The University of Texas Health Science Center at San Antonio·interventional·Posted Sep 23, 2011·Updated Jul 3, 2025
In Brief
A clinical study evaluating Dapagliflozin and Placebo for Insulin Sensitivity and Multiple Mitochondrial Dysfunctions Syndrome. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The purpose of this study is to examine the effect of the chronic treatment of type 2 diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin signaling/action and (2) oral glucose tolerance and beta cell function. Dapagliflozin is a potent, highly specific inhibitor of renal glucose transport \[SGLT2\].
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedSep 2011
Primary CompletionJun 2018
TodayJul 2026
First PostedSep 23, 2011
Enrollment StartMar 1, 2011
Primary CompletionJun 30, 2018
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 14.8 years ago
Interventions
Dapagliflozindrug
Treatment arm, 10 mg per day for 2 weeks
Placebodrug
Patients are treated with placebo